Tadatoshi Kubota

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Synthesis and biological activity of a series of 7^[(Z)-2-(2-aminothiazol-4-yl)-3-(substituted)2-propenoylamino]-3-cephem-4-carboxylic acids and their pivaloyloxymethyl esters are described. These acid compounds exhibited potent antibacterial activity against both Gram-positive and Gram-negative bacteria. Pivaloyloxymethyl esters of selected compounds in(More)
Among the prepared novel cephalosporin derivatives related to S-3578, a series of 7beta-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(Z)-ethoxyiminoacetamido]-3-[1-(aminoalkyl)-1H-pyrazolo[4,3-b]pyridinium-4-yl]methyl-3-cephem-4-carboxylate showed potent activity against both MRSA and Pseudomonas aeruginosa, and displayed good water solubility.
Among the prepared C-3' substituted-pyridinium cephalosporins, a series of 7beta-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-ethoxyiminoacetamido] cephalosporins bearing 4-[3-(aminoalkyl)-ureido]-1-pyridinium at C-3' showed highly potent antibacterial activity against MRSA and Pseudomonas aeruginosa.
A series of 7-aminothiadiazolylcephalosporins having a 1-(substituted)-1H-imidazo[4,5-b]pyridinium group at the C-3' position of the cephem nucleus were synthesized and evaluated for in vitro antibacterial activities. Among the cephalosporins prepared in this study,(More)
Symptoms of X-linked recessive diseases are usually observed in males, but also observed in some female carriers because of nonrandom X inactivation in which the mutated X chromosome is active and the normal X chromosomes is inactive. Therefore, it is important to investigate the patterns of X-chromosome inactivation (XCI) for clinical assessment of(More)
  • 1